Edition:
United Kingdom

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

5.25USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.25
Open
$5.25
Day's High
$5.25
Day's Low
$5.05
Volume
24,590
Avg. Vol
60,626
52-wk High
$8.25
52-wk Low
$2.55

Chart for

About

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is... (more)
No analyst recommendations are available for .

Overall

Beta: 0.72
Market Cap(Mil.): $493.14
Shares Outstanding(Mil.): 55.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology

* ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY

22 Feb 2018

BRIEF-Arbutus Enters Exclusivity Agreement With Roivant Sciences

* ARBUTUS ENTERS EXCLUSIVITY AGREEMENT WITH ROIVANT SCIENCES Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

15 Feb 2018

BRIEF-Arbutus Announces Departure Of CFO Bruce Cousins

* ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO

14 Feb 2018

BRIEF-Arbutus Consolidates HBV Business Around Warminster, PA Site

* ARBUTUS BIOPHARMA CORP - SITE CONSOLIDATION AND ORGANIZATIONAL RESTRUCTURING TO BETTER ALIGN ITS HBV BUSINESS IN WARMINSTER, PA

08 Feb 2018

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

16 Nov 2017

BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency

* Arbutus’ LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency (EMA) Source text for Eikon: Further company coverage:

13 Nov 2017

BRIEF-Arbutus Biopharma reports Q3 loss per share $0.21

* Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results

02 Nov 2017

BRIEF-Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement

* Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients

18 Oct 2017

BRIEF-Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

* Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million

02 Oct 2017

BRIEF-Arbutus announces topline results for ARB-1467 phase II Cohort 4

* Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4

25 Sep 2017

Earnings vs. Estimates